| HOME | HELP | CONTACT US | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Click here to read this article as a CME course
University of Texas MD Anderson Cancer Center, Houston, Texas, USA
Key Words. Gastric cancer • Taxane • Paclitaxel • Docetaxel • Oxaliplatin • Irinotecan • S-1 • Capecitabine
Correspondence: Jaffer A. Ajani, M.D., University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Box 426, Houston, Texas 77030, USA. Telephone: 713-792-2828; Fax: 713-745-1163; e-mail: jajani{at}mdanderson.org
Gastric cancer is the fourth most commonly diagnosed cancer and is the second leading cause of cancer death worldwide. More than 50% of patients undergo surgery, but even after a curative resection, 60% of patients relapse locally or with distant metastases. Despite the fact that many advances have occurred in the management of gastric cancer, it continues to carry a poor prognosis, amplifying the importance of palliative chemotherapy. When compared with best supportive care alone, combination chemotherapy yields a significant advantage in the management of advanced gastric cancer. However, no single regimen has emerged or been accepted as clearly superior over another. Numerous phase II studies have demonstrated promising results with newer agents including irinotecan, docetaxel, capecitabine, S-1, and oxaliplatin. Recently reported phase III results with these agents now demonstrate positive developments in the treatment options for patients with advanced gastric cancer.
This article has been cited by other articles:
 |
|
 |
|
  L. Celio, C. N. Sternberg, R. Labianca, I. La Torre, V. Amoroso, C. Barone, G. Pinotti, S. Cascinu, F. Di Costanzo, G. L. Cetto, et al. Pemetrexed in combination with oxaliplatin as a first-line therapy for advanced gastric cancer: a multi-institutional phase II study Ann. Onc., June 1, 2009; 20(6): 1062 - 1067. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. KONISHI, S. KIKUCHI, T. OCHIAI, H. IKOMA, T. KUBOTA, D. ICHIKAWA, H. FUJIWARA, K. OKAMOTO, C. SAKAKURA, T. SONOYAMA, et al. Latrunculin A Has a Strong Anticancer Effect in a Peritoneal Dissemination Model of Human Gastric Cancer in Mice Anticancer Res, June 1, 2009; 29(6): 2091 - 2097. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Li, C.-P. Yu, J.-t. Xia, L. Zhang, G.-X. Weng, H.-q. Zheng, Q.-l. Kong, L.-j. Hu, M.-S. Zeng, Y.-x. Zeng, et al. Sphingosine Kinase 1 Is Associated with Gastric Cancer Progression and Poor Survival of Patients Clin. Cancer Res., February 15, 2009; 15(4): 1393 - 1399. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. F. Aykan and E. Idelevich The role of UFT in advanced gastric cancer Ann. Onc., June 1, 2008; 19(6): 1045 - 1052. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J Lee, T Lim, J. Uhm, K. Park, S. Park, S. Lee, J. Park, Y. Park, H. Lim, T. Sohn, et al. Prognostic model to predict survival following first-line chemotherapy in patients with metastatic gastric adenocarcinoma Ann. Onc., May 1, 2007; 18(5): 886 - 891. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J Lee, W. Kang, J. Kwon, S. Oh, H. Lee, H. Kim, B. Park, H. Lim, M. Han, J. Park, et al. Phase II trial of irinotecan plus oxaliplatin and 5-fluorouracil/leucovorin in patients with untreated metastatic gastric adenocarcinoma Ann. Onc., January 1, 2007; 18(1): 88 - 92. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W Ichikawa and Y Sasaki Correlation between tumor response to first-line chemotherapy and prognosis in advanced gastric cancer patients Ann. Onc., November 1, 2006; 17(11): 1665 - 1672. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M Orditura, E Martinelli, G Galizia, C Carlomagno, G Aurilio, L Vecchione, E. Lieto, S De Placido, G Catalano, F Ciardiello, et al. Weekly docetaxel and capecitabine is not effective in the treatment of advanced gastric cancer: a phase II study Ann. Onc., October 1, 2006; 17(10): 1529 - 1532. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | CONTACT US | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| THE ONCOLOGIST | STEM CELLS | CME | ALPHAMED PRESS JOURNALS |
